Enzyme immunoassay for the quantitative determination of free Nivolumab (Opdivo®) in serum and plasma.
This kit has been especially developed for the quantitative determination of Nivolumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Nivolumab Drug Bank Accession Number is DB09035.
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, hepatocellular carcinoma, and esophageal cancer. The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact firstname.lastname@example.org
|Required Volume (µl)||10|
|Total Time (min)||70|
|Detection Limit (ng/mL)||30|
|Spike Recovery (%)||Between 85-115|
|Shelf Life (year)||1|
|Storage conditions||Store at +4°C. Please refer to protocols.|
|Shipping conditions||At room temperature|
|Instructions For Use||Download|
|Safety Data Sheet (SDS)||Download|
Publications with this drug
|Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in routine clinical practice. A pilot study." Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 44.3 (2020): 81-86.||Visit Link|
|Nieto, Juan C., et al. "Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy." Leukemia (2020): 1-6.||Visit Link|
|Abe, Kazuki, et al. "Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion." Analytical Methods 12.1 (2020): 54-62.||Visit Link|
|Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience." DEVELOPMENTAL IMMUNOTHERAPY AND TUMOR IMMUNOBIOLOGY (2019)||Visit Link|
|García Gil S, Ramos Díaz R., ANÁLISIS DE LA CONCENTRACIONES PLASMÁTICAS DE NIVOLUMAB EN EL TRATAMIENTO DEL CPNM||Visit Link|